Recombinant Monoclonal Anti-CD45RO Antibody, Mouse (4C8)

사용자 리뷰
제품 번호/규격
가격
수량
HGS-S249-20ul
$130.00
HGS-S249-100ul
$440.00
ETA of in-stock products:2 business days
총 항목 수 제품 금액$ 0

제품 세부정보

  • Background

    Recombinant Monoclonal Anti-CD45RO Antibody, Mouse (4C8) is a CD45RO primary antibody for IHC application. CD45RO (UCHL1, ubiquitin carboxyl terminal esterase L1) is the shortest isoform of a receptor-type protein tyrosine phosphatase, CD45 glycoprotein. CD45 is crucial in lymphocyte development and antigen signaling, serving as an important regulator of Src-family kinases, promotes cell survival by modulating integrin-mediated signal transduction pathway and is also involved in DNA fragmentation during apoptosis.

  • Product Specifications

    Host Species
    Mouse
    Isotype
    IgG
    Clone
    4C8
    Application
    IHC
    Property
    1:500
    State
    Liquid
    Positive Control
    Human Tonsil Tissues
    Clonality
    Monoclonal
    Research Field
    Cancer Drug Targets
    Source
    Mouse
    Synonym
    CD45RO
  • Experiment Protocol

    LEICA Experiment Protocol(Manual)

  • Storage

    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. The shelf life is 30 days from the date of opening.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

고객님도 확인한 상품

데이터 표시

Typical Data
  • Control Sample

     CD45RO CONTROL SAMPLE

    Immunohistochemical analysis of paraffin embedded Human tonsil tissue labelled with HGS-S249 at 1/500 dilution.
    Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

  • Cancer Sample

     CD45RO CANCER SAMPLE
     CD45RO CANCER SAMPLE
     CD45RO CANCER SAMPLE

    Immunohistochemical analysis of paraffin embedded human cancer tissue labelled with HGS-S249 at 1/500 dilution.
    Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

사용자 리뷰
댓글 남기기

프론티어 진행

 
의약품 개발 진행
  • 영어 이름:

    Leukocyte common antigen

  • 카테고리:

  • 상장 의약품 수:

    0 상세

  • 임상 의약품 수:

    4 상세

  • 최고 개발 단계:

    Phase 3 Clinical

연락하기
신약 후보물질 라이선싱
더 많이 알아보기
  • 기본 제품 정보
  • 제품 세부정보
  • 고객님도 확인한 상품
  • 데이터 표시
  • 사용자 리뷰
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호